Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
MMWR Morb Mortal Wkly Rep ; 66(46): 1276-1280, 2017 Nov 24.
Article de Anglais | MEDLINE | ID: mdl-29166363

RÉSUMÉ

In 1988, the World Health Assembly launched the Global Polio Eradication Initiative. Among the three wild poliovirus serotypes, only wild poliovirus (WPV) type 1 (WPV1) has been detected since 2012. Since 2014, Pakistan, Afghanistan, and Nigeria remain the only countries with continuing endemic WPV1 transmission. This report describes activities conducted and progress made toward the eradication of poliovirus in Pakistan during January 2016-July 2017 and provides an update to previous reports (1,2). In 2016, Pakistan reported 20 WPV1 cases, a 63% decrease compared with 54 cases in 2015 (3). As of September 25, 2017, five WPV1 cases have been reported in 2017, representing a 69% decline compared with 16 cases reported during the same period in 2016 (Figure 1). During January-September 2017, WPV1 was detected in 72 of 468 (15%) environmental samples collected, compared with 36 of 348 (9%) samples collected during the same period in 2016. WPV1 was detected in environmental samples in areas where no polio cases are being reported, which indicates that WPV1 transmission is continuing in some high-risk areas. Interruption of WPV transmission in Pakistan requires maintaining focus on reaching missed children (particularly among mobile populations), continuing community-based vaccination, implementing the 2017-2018 National Emergency Action Plan (4), and improving routine immunization services.


Sujet(s)
Éradication de maladie , Poliomyélite/prévention et contrôle , Surveillance de la population , Enfant d'âge préscolaire , Humains , Programmes de vaccination , Calendrier vaccinal , Nourrisson , Pakistan/épidémiologie , Poliomyélite/épidémiologie , Poliovirus/génétique , Poliovirus/isolement et purification , Vaccin antipoliomyélitique oral/administration et posologie , Vaccin antipoliomyélitique oral/effets indésirables , Vaccins antipoliomyélitiques/administration et posologie , Vaccins antipoliomyélitiques/effets indésirables
2.
Emerg Infect Dis ; 23(1): 38-45, 2017 01.
Article de Anglais | MEDLINE | ID: mdl-27983502

RÉSUMÉ

During November-December 2015, as part of the 2015 cholera outbreak response in Iraq, the Iraqi Ministry of Health targeted ≈255,000 displaced persons >1 year of age with 2 doses of oral cholera vaccine (OCV). All persons who received vaccines were living in selected refugee camps, internally displaced persons camps, and collective centers. We conducted a multistage cluster survey to obtain OCV coverage estimates in 10 governorates that were targeted during the campaign. In total, 1,226 household and 5,007 individual interviews were conducted. Overall, 2-dose OCV coverage in the targeted camps was 87% (95% CI 85%-89%). Two-dose OCV coverage in the 3 northern governorates (91%; 95% CI 87%-94%) was higher than that in the 7 southern and central governorates (80%; 95% CI 77%-82%). The experience in Iraq demonstrates that OCV campaigns can be successfully implemented as part of a comprehensive response to cholera outbreaks among high-risk populations in conflict settings.


Sujet(s)
Conflits armés , Vaccins anticholériques/administration et posologie , Choléra/prévention et contrôle , Épidémies de maladies , Population de passage et migrants , Couverture vaccinale/statistiques et données numériques , Administration par voie orale , Adolescent , Adulte , Sujet âgé , Enfant , Enfant d'âge préscolaire , Choléra/épidémiologie , Choléra/immunologie , Choléra/anatomopathologie , Femelle , Humains , Nourrisson , Iraq/épidémiologie , Mâle , Vaccination de masse , Adulte d'âge moyen , Camps de réfugiés , Couverture vaccinale/organisation et administration , Vibrio cholerae/pathogénicité , Vibrio cholerae/physiologie
3.
Ear Nose Throat J ; 91(1): 28-33, 2012 Jan.
Article de Anglais | MEDLINE | ID: mdl-22278867

RÉSUMÉ

We conducted a study to determine the prevalence of vocal symptoms in snorers. A total of 30 patients with a history of snoring were investigated for the presence or absence of three vocal symptoms immediately after they awoke from sleep: hoarseness, voice weakness, and other changes in voice quality. All patients were also asked to complete a voice-related quality-of-life (V-RQOL) questionnaire. Findings were compared with those of an age- and sex-matched control group of 30 nonsnorers. The most common vocal symptom in the snoring group was hoarseness, which occurred in 11 patients (36.7%); voice weakness and other voice quality changes were present in 8 snorers each (26.7%). In the control group, the most common vocal symptom was voice weakness, which was present in 7 subjects (23.3%); 5 controls (16.7%) experienced other changes in voice quality, and 3 controls (10.0%) experienced hoarseness. The difference between the prevalence of hoarseness in the two groups was statistically significant (p = 0.030), and the differences in voice weakness and other voice quality changes were not. The mean V-RQOL score was 87.50 ± 26.89 in the snoring group and 96.00 ± 5.82 in the control group-again, not a statistically significant difference. Finally, we found no association between any of the three vocal symptoms and the prevalence of mouth breathing, the level of snoring loudness, and the mean number of snores per minute. We conclude that snorers are more likely to experience hoarseness than are nonsnorers.


Sujet(s)
Ronflement/complications , Troubles de la voix/étiologie , Adulte , Femelle , Enrouement/étiologie , Humains , Mâle , Adulte d'âge moyen , Qualité de vie , Enquêtes et questionnaires
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...